Disease & disorder

amyloidosis

MONDO:0019065

A disorder characterized by the localized or diffuse accumulation of amyloid protein in various anatomic sites. It may be primary, due to clonal plasma cell proliferations; secondary, due to long standing infections, chronic inflammatory disorders, or malignancies; or familial. It may affect the nerves, skin, tongue, joints, heart, liver, spleen, kidneys and adrenal glands.

Clinical trials37
Recruiting10
Drug concepts studied7
Synonyms5

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…
Background context

Amyloidosis

Amyloidosis is a group of diseases in which abnormal proteins, known as amyloid fibrils, build up in tissue. There are several non-specific and vague signs and symptoms associated with amyloidosis. These include fatigue, peripheral edema, weight loss, shortness of breath, palpitations, and feeling faint with standing. In AL amyloidosis, specific indicators can include enlargement of the tongue and periorbital purpura. In wild-type ATTR amyloidosis, non-cardiac symptoms include: bilateral carpal tunnel syndrome, lumbar spinal stenosis, biceps tendon rupture, small fiber neuropathy, and autonomic dysfunction. There are about 36 different types of amyloidosis, each due to a specific protein misfolding. Within these 36 proteins, 19 are grouped into localized forms, 14 are grouped as systemic forms, and three proteins can identify as either. These proteins can become irregular due to genetic effects, as well as through acquired environmental factors. The four most common types of systemic amyloidosis are light chain (AL), inflammation (AA), dialysis-related (Aβ2M), and hereditary and old age (ATTR and wild-type transthyretin amyloid). Diagnosis may be suspected when protein is found in the urine, organ enlargement is present, or problems are found with multiple peripheral nerves and it is unclear why. Diagnosis is confirmed by tissue biopsy. Due to the variable presentation, a diagnosis can often take some time to reach. Treatment is geared towards decreasing the amount of the involved protein. This may sometimes be achieved by determining and treating the underlying cause. A...

Background only. Canonical identity remains MONDO; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

37 shown
Cardiac Magnetic Resonance and Echocardiography Study With AcoramidisNCT07695701 · 2026-07-01
RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)NCT07589595 · 2026-05-20
RECRUITING
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding AreasNCT07285044 · 2025-12-18
RECRUITING
Generative AI Impact on Rheumatoid Arthritis Complications DiagnosisNCT07301892 · 2025-10-01
RECRUITING
[18F]FT8 PET Imaging in Immunoglobulin Light Chain AmyloidosisNCT07232459 · 2025-07-21
RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR VariantNCT06563895 · 2025-05-12
RECRUITING
Institutional Registry of Rare DiseasesNCT06573723 · 2024-07-01
RECRUITING
Pan-Amyloid PET/CT in Various Amyloid-Related DiseaseNCT07130565 · 2023-11-01
RECRUITING
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEFNCT05577819 · 2020-10-02
RECRUITING
Beta Amyloid PET/CT in Various Aβ-Related DiseaseNCT06725706 · 2012-09-01
RECRUITING
Impact of a Cardiac Rehabilitation Program on Patients With Cardiac AmyloidosisNCT07494942 · 2026-12-30
NOT_YET_RECRUITING
To Evaluate the Long-term Safety and Tolerability of Acoramidis in Participants With Newly Diagnosed ATTR-CM (ACT-EARLY OLE)NCT07116473 · 2026-11-01
NOT_YET_RECRUITING
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)NCT07843459 · 2026-10-01
NOT_YET_RECRUITING
A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's DiseaseNCT07787182 · 2026-09-01
NOT_YET_RECRUITING
A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's DiseaseNCT07787169 · 2026-09-01
NOT_YET_RECRUITING
Fractional CO₂ Laser for Primary Cutaneous AmyloidosisNCT07815132 · 2024-09-10
COMPLETED
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare DiseasesNCT06539169 · 2024-06-10
UNKNOWN
Amyloidosis Incidence in High-Risk Cardiac Device PatientsNCT06186167 · 2024-01-29
UNKNOWN
18F-florbetaben PET-CT to Non-invasively Diagnose Cardiac AL AmyloidosisNCT06048601 · 2023-01-26
UNKNOWN
Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's DiseaseNCT05138848 · 2022-01-03
COMPLETED
Selinexor for Treatment of Light Chain Amyloidosis With Relapsed/Refractory DiseaseNCT04984330 · 2021-12-01
WITHDRAWN
Transdermal Trigeminal Electrical Neuromodulation on Mild Cognitive Impairment With InsomniaNCT05200897 · 2021-11-03
UNKNOWN
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research InitiativesNCT05635266 · 2021-10-26
UNKNOWN
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) in Patients With Idiopathic Peripheral NeuropathyNCT04985734 · 2021-10-01
UNKNOWN
CLearing Alzheimer's Disease Molecular Pathology Without MedicationsNCT04913454 · 2021-08-01
UNKNOWN
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to DaratumumabNCT04270175 · 2021-04-14
ACTIVE_NOT_RECRUITING
Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal AmyloidosisNCT04760171 · 2021-02-01
UNKNOWN
Atrial Amyloid May Influence Outcomes in Patients Undergoing Surgical Aortic Valve ReplacementNCT07105501 · 2020-11-03
COMPLETED
Detection of Amyloid Deposits in the Wrist by MRI With Mapping and High Resolution Sequences in Systemic Amyloidosis (AMYLOCARP)NCT05150353 · 2020-01-24
COMPLETED
Screening for Systemic Amyloidosis Via the Ligamentum FlavumNCT03923920 · 2019-05-01
COMPLETED
Evaluation of MyoStrain™ in Clinical PracticeNCT03825224 · 2019-04-15
COMPLETED
Efficacy and Safety of AG10 in Subjects With Transthyretin Amyloid CardiomyopathyNCT03860935 · 2019-03-19
COMPLETED
Monitoring of Early Disease Progression in Hereditary Transthyretin AmyloidosisNCT03431896 · 2018-02-01
COMPLETED
Platelet Reactivity, B-amyloid, MOTS-c and Mortality of Type II Diabetics With CADNCT04027712 · 2014-01-01
UNKNOWN
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL AmyloidosisNCT01383759 · 2011-06-24
COMPLETED
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) AmyloidosisNCT01083316 · 2009-09-01
COMPLETED
B-Receptor Signaling in CardiomyopathyNCT01135849 · 2008-11-01
COMPLETED

Leading sponsors

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.